Depression is a serious medical illness that affects a person’s mental, emotional and physical well-being. The patient feels a loss of interest and has a feeling of sadness. Many people have trouble doing daily activities. Hs can also cause various physical an emotional problems. Several drugs are used for treating depression like antidepressants. These drugs help in relieving the symptoms of anxiety disorders, seasonal affective disorder and social anxiety disorder.
Global treatment resistant depression market, is forecast to be valued at US$ 1,180.0 Mn in 2022 and is estimated to exhibit a CAGR of 3.4% during the forecast period.
Request FREE Sample Report (Including Full TOC, Table & Figures) @
Impact of COVID-19:
COVID-19 was initially reported in China, in December, 2019. On March 11, 2020, the World Health Organization declared this as a pandemic and the Epidemiological Update, for Coronavirus by the WHO mentioned that till June 6, 2022, almost 532 million cases of COVID-19 were reported and it also caused 6 million deaths globally.
The pandemic also affected many clinical trial on various drugs that were used for depression by several research institutes, this had a negative impact on many research and development activities being carried out on new drugs worldwide. For instance,
Medidata technology and solutions, conducted electronic survey on 9,952 of their staff members on April 23, 2020, at several trial sites worldwide. This survey showed a response rate of 10.3%, and out of 1,030 participants only a few answered the survey. 58.3% respondents of the survey belonged to the U.S. (North America), 23.8% were from Asia Pacific, which was followed by Europe with 8.1%, 7.1% were from South & Central America and Middle East & Africa accounted for 2.7%. Investigators, clinical nurses, study coordinators and site managers were a part of the study. This survey also showed that COVID-19 had affected the ability to carry out clinical trials and also impacted starting of new trials.
Rising prevalence of depression is estimated to propel growth of global treatment resistant depression market over the forecast period. For instance, the Journal of Clinical Psychiatry published an article in 2021, stating that 8.9 million individuals were treated with major depressive disorder and almost 2.8 million individuals had treatment-resistant depression in the U.S.
Furthermore, rising launches of generic products by major players is estimated to augment growth of the global treatment resistant depression market over the forecast period. For instance, Dr. Reddy’s Laboratories Ltd. declared the launch of Bupropion Hydrochloride Extended-Release Tablets in September 2019. These are generic version of Zyban Extended-Release Tablets, which have been approve by the U.S. FDA.
Download PDF Brochure with Latest Insights @
Global treatment resistant depression market is estimated to exhibit a CAGR of 3.4% during the forecast period, due to the rising incidences of treatment-resistant depression. For instance, Frontiers Media S.A, published an article on 2 March 2022, stating the prevalence of treatment-resistant depression was 21% in Mexico, 32% was reported in Colombia, Argentina reported 33%, and 40% in Brazil.
Key players active in the global treatment resistant depression market are Aurobindo Pharma Ltd, AbbVie Inc., AstraZeneca, Lupin, H. Lundbeck A/S, Eli Lilly and Company, Otsuka Holdings Co., Ltd., GlaxoSmithKline Plc., Viatris Inc., Pfizer Inc., Merck & Co., Inc., Bausch Health Companies Inc., Johnson & Johnson and Sanofi, Mallinckrodt.
Reasons to buy this Treatment Resistant Depression Market Report
☑ It attempts an analysis of the competing scenario.
☑ The current and exceptional product revenue market.
☑ An in-depth data on the regional investigation and competitive landscape structure.
☑ It benefits in creating an awareness of the important key product segments.
☑ The marketing strategies, opportunities, and development factors are explained.
☑ Treatment Resistant Depression market size estimation and recent advancements in the industry are explained.
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/5196
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Treatment Resistant Depression Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Treatment Resistant Depression Industry Impact
Chapter 2 Global Treatment Resistant Depression Competition by Types, Applications, and Top Regions and Countries
2.1 Global Treatment Resistant Depression (Volume and Value) by Type
2.3 Global Treatment Resistant Depression (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Treatment Resistant Depression Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Treatment Resistant Depression Market Analysis
Chapter 6 East Asia Treatment Resistant Depression Market Analysis
Chapter 7 Europe Treatment Resistant Depression Market Analysis
Chapter 8 South Asia Treatment Resistant Depression Market Analysis
Chapter 9 Southeast Asia Treatment Resistant Depression Market Analysis
Chapter 10 Middle East Treatment Resistant Depression Market Analysis
Chapter 11 Africa Treatment Resistant Depression Market Analysis
Chapter 12 Oceania Treatment Resistant Depression Market Analysis
Chapter 13 South America Treatment Resistant Depression Market Analysis
Chapter 14 Company Profiles and Key Figures in Treatment Resistant Depression Business
Chapter 15 Global Treatment Resistant Depression Market Forecast (2022-2028)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
533 Airport Boulevard, Suite 400,
Burlingame, CA 94010, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027